Fireside Project’s Post

Why Lykos Therapeutics (formerly MAPS PBC) psychedelic-assisted therapy protocol may not be scalable? (as explained by Joshua White, founder and Executive Director of Fireside Project. As more people look to psychedelic medicines to improve their health and well-being, it’s clear that a model that requires two therapists to sit with every individual receiving psychedelic therapy is not scalable. Josh joined Amanda S. on the Ibogaine Uncovered podcast to discuss the role and value of non-clinical support in the psychedelic space, and to share about his recent ibogaine experience at Beond. Joshua underscores the need for more non-clinical support in the psychedelic realm, including coaches and peer supporters like the ones at Fireside Project. He suggests that peer support is not only more financially accessible but may also better meet the needs of individuals undergoing psychedelic journeys more of what they need before and after a transformative experience, especially depending on a peer’s familiarity with psychedelics. As Josh experienced during his time at Beond, having the right support, whether clinical or not, helps create a safe container for a psychedelic journey – whether that journey takes place in the Amazon rainforest, or in a hospital bed with noise-canceling headphones and an eye mask at an ibogaine treatment center in Cancun. For example, with Ibogaine, there is no need for a therapist during the treatment. At Beond, there are coaches before and after the treatment. What we witnessed at Beond, peer-to-peer support plays a huge role in healing. What are your thoughts on the ideal model for psychedelic therapy? Should we stick to the MAPS protocol requiring two therapists, or is there room for non-clinical support to play a crucial role? Are both possible for different situations and needs? #psychedelictherapy #maps #psychedelicresearch #harmreduction #firesideproject

Having a scalable models is important. It’s known that the facilitators are the bottleneck as the masses are knocking on the door. While I support the notion of having non-clinical support to further access and lower costs; how does our society qualify these folks? Regardless of criteria’s, qualifications, standards etc., one thing is for certain, peer support - peer support - peer support !! The more practitioners we have providing services (non-clinical and clinical alike), the more variation and opportunity for collaboration. #PGN #PGNetwork #PeerSupport #WisdomCircles

𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐏𝐃𝐅 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 𝐀𝐮𝐭𝐢𝐬𝐦 𝐒𝐩𝐞𝐜𝐭𝐫𝐮𝐦 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐆𝐮𝐢𝐝𝐞@ https://lnkd.in/guUEqmWq The Autism Spectrum Disorder Treatment Market is a rapidly growing industry driven by the increasing prevalence of autism spectrum disorder (ASD) worldwide. With advancements in medical research and technology, there are now more treatment options available for individuals with ASD than ever before. Some of the key factors driving the growth of the ASD treatment market include the rising awareness about early diagnosis and intervention, increased government funding for research and development, and a growing acceptance of different therapeutic approaches. In addition to traditional therapies such as behavioral therapy and speech therapy, there are also emerging treatments such as medication, dietary interventions, and alternative therapies like music therapy and animal-assisted therapy. The market is also seeing a rise in digital health solutions, including telehealth services and mobile apps designed to support individuals with ASD and their families. Overall, the Autism Spectrum Disorder Treatment Market is expected to continue expanding as more research is conducted and new treatment options become available. This presents both opportunities for healthcare providers and pharmaceutical companies to innovate and improve outcomes for individuals with ASD. Major Players included in Study are  Johnson & Johnson (The Janssen Pharmaceutical Companies of Johnson & Johnson), Pfizer, Roche, AstraZeneca, Eli Lilly and Company, Allergan (now part of AbbVie), Novartis, Bristol Myers Squibb, dfusion Inc., Jazz Pharmaceuticals, Bristol Myers Squibb, Curemark, LLC, Axial Therapeutics, Inc., Cognoa, EarliTec Diagnostics, Inc. #AutismTreatment #AutismSpectrumDisorder #ASD #Neurodevelopment #MentalHealth #AutismAwareness #Pharmaceuticals #Healthcare #Neuroscience #BehavioralHealth #AutismCare #AutismResearch #JohnsonAndJohnson #Pfizer #Roche #AstraZeneca #EliLilly #Allergan #AbbVie #Novartis #BristolMyersSquibb #dfusionInc #JazzPharmaceuticals #Curemark #AxialTherapeutics #Cognoa #EarliTecDiagnostics

Exciting strides are being made in the realm of mental health treatment, and a recent MarketBeat article penned by Ari Zoldan delves into the forefront of #innovation. With the psychiatric and anxiety drug market projected to soar from $20 billion to $30 billion by 2032, the need for transformative solutions has never been more apparent. This insightful piece spotlights five trailblazing biotech companies - Sage Therapeutics, atai Life Sciences, Incannex Healthcare Inc, NRx Pharmaceuticals, Inc., and Enveric Biosciences, Inc. - all committed to addressing the evolving landscape of mental health. From SAGE Therapeutics' groundbreaking work on GABA and NMDA receptors to Incannex's pioneering psilocybin-based PsiGAD for anxiety, these companies are paving the way for life-changing treatments. Curious to learn more? Check out the full article here: https://lnkd.in/gbfimMNg 💬 What are your thoughts on these amazing advancements in mental health? Please share them in the comments below. 👇 #BiotechInnovation #MentalHealthRevolution #HealthcareForward

"The path to equitable neurological patient engagement is complex and requires a multifaceted approach. This includes diversifying clinical trial locations and decentralizing the clinical trial data collection so that we not only invite diverse populations to participate in clinical trial design and recruitment efforts but that we also remove the barriers that prevent their participation." Read more below on how UCB is improving #diversity in neurological clinical trials. #pharma #innovation

Big news from MindMed's kitchen, the #phase2b study is complete. ;) The 100 microgram dose level of MM-120 (lysergide d-tartrate) demonstrated the strongest clinical activity, showing large and statistically significant reductions in all analyzed endpoints at all timepoints post-baseline, including a: - 21.3-point reduction in HAM-A scores from baseline (7.6 points over placebo) and an effect size of d=0.88 (more than double that of SRIs and benzodiazepines) - 78% clinical response rate (that is, a HAM-A reduction of 50% or greater) at week 4 - 50% clinical remission rate (that is, a HAM-A score of 7 or less) at week 4 - Reduction in CGI-S scores from “markedly ill” to “borderline ill” through week 4 All the above was achieved in absence of a concurrent therapeutic intervention. Congratulations should be aimed toward our drug discovery & clinical teams. #mentalhealth #anxiety #clinicaltrials https://lnkd.in/dr69f42d

Did you know that cannabis-based medicines can be prescribed by specialist for some conditions? 💊 I didn’t until I read around guidance published in 2018 by the Department of Health. This was after a patient with spasticity presented to me in GP. She had a background of multiple sclerosis and had tried baclofen but suggested CBD as a possible treatment. I then contacted the local neurology team for some advice. Cannabis based products can only be prescribed by those on the specialist register. Some indications include: - chemotherapy induced nausea and vomiting. - spasticity in patients with MS - severe treatment resistant epilepsy. As primary care physicians we should NOT be offering these products. However, if we are asked about them then we should seek further guidance from oncologists/neurologists.

Just chatted with Business Insider about the exciting world of AI in mental healthcare! 📰👨🏾⚕️ While it won't replace human connection, AI-powered prescription digital therapeutics can engage patients, extend personalized care, and actually treat disease! 💊📲 Haig Goenjian, MD, lead physician investigator in our clinical trials, shared "At the end of our studies, many patients asked how they can continue to use this digital therapeutic." 👏🏾⚡ Read the full article to see why! https://lnkd.in/ep4uZgWj #mentalhealth #digitaltherapeutics #AItherapy

This #MentalHealthAwarenessWeek, I’m cautiously celebrating a major development that has the potential to revolutionise how we treat mental health conditions. AbbVie and Gilgamesh Pharmaceuticals have joined forces in a deal worth up-to $2 billion to develop next-generation neuroplasticity therapies. For too long, neuropsychiatry has been an under-resourced area. This collaboration marks a significant shift, bringing together AbbVie's expertise with Gilgamesh's innovative research platform to unlock the potential of these transformative drugs. Classic psychedelics, as well as non-hallucinogenic compounds, have shown promise in treating treatment-resistant conditions, and this new generation holds the potential to revolutionise mental healthcare. This partnership between a major pharmaceutical player and a pioneering biotech company is a promising sign. 𝗛𝗢𝗪𝗘𝗩𝗘𝗥, it's crucial that patient well-being remains the priority... We've seen the devastating impact of mental illness on countless lives, and we must take responsible steps to revolutionise how we treat these conditions. I truly hope this deal paves the way for more responsible collaborations and investments in this space, prioritising positive patient outcomes 𝗼𝘃𝗲𝗿 shareholder interests. #innovation #technology #future

Last month, Swing Therapeutics presented data from a real-world trial of Stanza, an FDA-cleared digital behavioral therapy for treatment of #fibromyalgia symptoms, at the 2023 annual meeting of the Association for Behavioral and Cognitive Therapies. The results demonstrated Stanza’s clinically meaningful benefit in addressing unmet needs for fibromyalgia patients, specifically, showing the treatment’s impact on symptoms that most limit patient quality of life (QoL). After using the smartphone-based treatment, which provides Acceptance of Commitment Therapy and additional cognitive behavioral therapy-based interventions, 87% of participants improved in at least one QoL-limiting symptom. 3x patients reported QoL satisfaction after treatment. See the full post below, and learn more about the benefits of personalized, patient-centered care in addressing fibromyalgia symptoms.